Understanding how reduced stress affects non-small cell lung cancer
Deciphering the Role of Reductive Stress in Non Small Cell Lung Cancer
['FUNDING_R37'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-10986111
This study is looking at how certain stress levels in lung cancer cells affect their growth, especially by focusing on a protein called NRF2 that helps protect cells from damage, and it's for people with non-small cell lung cancer who want to understand more about how their cancer might behave.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10986111 on ClinicalTrials.gov |
What this research studies
This research investigates the balance of oxidative and reductive stress in non-small cell lung cancer (NSCLC) cells, focusing on how these conditions influence cancer cell growth. The team is particularly interested in the NRF2 transcription factor, which helps regulate the body's antioxidant response. By activating NRF2 in various NSCLC cell lines, they aim to uncover how this pathway affects cancer proliferation, especially in cases where the KEAP1 gene is not mutated. The study employs advanced techniques like CRISPR screening to identify key genes involved in this process.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, particularly those with wildtype KEAP1.
Not a fit: Patients with other types of lung cancer or those whose tumors have mutations in the KEAP1 gene may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that target the unique metabolic pathways of non-small cell lung cancer.
How similar studies have performed: While the role of oxidative stress in cancer has been widely studied, the exploration of reductive stress in NSCLC is relatively novel and has not been extensively tested.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BAR-PELED, LIRON — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: BAR-PELED, LIRON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapeutic, anti-cancer therapy